

Table 1: Drugs graded by eligibility for trial by intrathecal administration for medulloblastoma (ref 37 - Conroy et al 2010)

Agents under trial

Liposomal cytarabine (Depocyte®)*

Mafosfamide*

Agents suitable for clinical trial

Carboplatin

Etoposide

Nimustine (ACNU)

Drugs requiring further investigation before clinical trial

Floxuridine (FDUrd)

4-hydroperoxy-cyclophosphamide

Drugs requiring further investigation, lower priority

Diaziquone

Mercaptopurine

Rubitecan

Topotecan

Radio-immunotherapy ¹³¹I-3F8 murine monoclonal antibody

Drug with insufficient information to grade

Temozolomide

* This drug has now been withdrawn from production by the manufacturer